Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics

doi:10.1080/1744666X.2019.1705785

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 其他文獻 > Item 310902500/25039

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/25039

Title:	Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics
Authors:	Chiu, YM;Chen, DY
Keywords:	Infection risk;treatment;non-biologics;biologics;inflammatory arthritis
Date:	2020
Issue Date:	2022-08-09T09:27:27Z (UTC)
Publisher:	TAYLOR & FRANCIS LTD
ISSN:	1744-666X
Abstract:	Introduction: Despite the therapeutic effectiveness of biologics targeting immune cells or cytokines in patients with inflammatory arthritis, which reflects their pathogenic roles, an increased infection risk is observed in those undergoing biological treatment. However, there are limited data regarding the comparison of infection risks in inflammatory arthritis patients treated with non-biologics (csDMARDs), biologics (bDMARDs), including tumor necrosis factor (TNF) inhibitors and non-TNF inhibitors, or targeted synthetic (ts)DMARDs. Areas covered: Through a review of English-language literature as of 30 June 2019, we focus on the existing evidence on the risk of infections caused by bacteria, Mycobacterium tuberculosis, and hepatitis virus in inflammatory arthritis patients undergoing treatment with csDMARDs, bDMARDs, or tsDMARDs. Expert opinion: While the risks of bacterial and mycobacterial infection are increased in arthritis patients treated with csDMARDs, the risks are further higher in those receiving bDMARDs therapy, particularly TNF inhibitors. Regarding HBV infection, antiviral therapy may effectively prevent HBV reactivation in patients receiving bDMARDs, especially rituximab. However, more data are needed to establish effective preventive strategies for HBsAg-negative/HBcAb-positive patients. It seems safe to use cyclosporine and TNF inhibitors in patients with HCV infection, while those undergoing rituximab therapies should be frequently monitored for HCV activity.
URI:	http://dx.doi.org/10.1080/1744666X.2019.1705785 https://www.webofscience.com/wos/woscc/full-record/WOS:000506555200001 https://ir.csmu.edu.tw:8080/handle/310902500/25039
Relation:	EXPERT REVIEW OF CLINICAL IMMUNOLOGY ,2020 ,v16 ,issue 2 ,p207-228
Appears in Collections:	[中山醫學大學研究成果] 其他文獻

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	189	View/Open

Loading...